行为矫正联合哌罗匹隆治疗对精神分裂症患者社会功能及泌乳素水平、体重的影响

摘要/Abstract

摘要： 目的：探讨行为矫正联合哌罗匹隆治疗对精神分裂症患者社会功能及催乳素、体重的影响。方法：将62例精神分裂症患者随机分为两组，对照组(n=31）给予哌罗匹隆治疗，治疗组(n=31）在此基础上给予行为矫正治疗，包括生活自理、社会生活及社交能力训练，持续3个月。采用阳性和阴性症状量表（PANSS）、个人和社会功能量表（PSP）评估患者精神症状及社会功能方面的变化，检测患者泌乳素及体重变化，采用副反应量表（TESS）评估不良反应严重程度。结果：干预3个月后，两组患者PANSS总分减分率较干预1个月后增加，且治疗组PANSS总分减分率高于对照组(P<0.05)。干预1、3个月后，治疗组PSP评分、TESS评分较干预前均改善，且干预3个月后治疗组PSP评分高于对照组(P<0.05)，TESS评分低于对照组(P<0.05)。干预前、干预1、3个月两组患者泌乳素水平、体重组内及组间同期比较，差异均无统计学意义（P>0.05）。结论：精神分裂症患者在哌罗匹隆治疗基础上引入行为矫正治疗，可进一步改善患者的精神症状、社会功能，对泌乳素水平和体重影响较小。

关键词: font-size:medium, ">精神分裂症；行为矫正治疗；哌罗匹隆；内分泌；社会功能

Abstract: Objective：To explore the influence of behavior modification therapy combined with perospirone on the social function, prolactin level and body weight in the patients with schizophrenia (SCZ). Methods：62 SCZ patients were randomly divided into two groups:the control group (n=31) was given perospirone, and the treatment group (n=31) was given behavior modification therapy on the base of the control group, including activities of daily living, social life and social ability training, all for 3 months. Positive and negative symptom scale (PANSS) and personal and social performance scale (PSP) were used to evaluate the psychiatric symptoms and social function, and the prolactin level and body weight of the patients were measured.The severity of adverse reactions was assessed using the TESS scale. Results：3 months after intervention, the total score reduction rate of PANSS in the two groups was higher lower than that at 1 month after intervention, and the total score reduction rate of PANSS in the treatment group was higher lower than that in the control group (P<0.05). After 1 and 3 months of intervention, the PSP score and TESS score of patients in the treatment group was significantly improved compared with those before intervention.After the 3 months, PSP score of the treatment group was higher than that in the control group(P<0.05), and the TESS score in the treatment group was lower than that in the control group (P<0.05).There were no statistical differences in prolactin level and body weight before intervention, 1 and 3 months after intervention between and within the two groups(P>0.05). Conclusion：Behavior modification therapy combined with perospirone can further improve the mental symptoms, social function of SCZ patients, and has little effect on the prolactin level and body weight.

Key words: Schizophrenia, Behavior modification therapy, Perospirone, Endocrine, Social function

中图分类号:

冒海瀛, 周争轶, 杨建军. 行为矫正联合哌罗匹隆治疗对精神分裂症患者社会功能及泌乳素水平、体重的影响[J]. 中国医药导刊, 2022, 24(2): 152-155.

MAO Haiying, ZHOU Zhengyi, YANG Jianjun. Effect of Behavior Modification Therapy Combined with Perospirone on the Social Function, Prolactin Level and Body Weight in the Patients with Schizophrenia[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(2): 152-155.

参考文献

[1]Ayano G, Tesfaw G, Shumet S. The prevalence of schizophrenia and other psychotic disorders among homeless people:a systematic review and meta-analysis[J]. BMC Psychiatry, 2019,19(1):370-375.
     [2]中国神经科学学会精神病学基础与临床分会精神分裂症临床研究联盟.抗精神病药所致高泌乳素血症干预对策的专家共识[J]. 中华精神科杂志, 2021, 54(3):163-169.
     [3]梁碧森.氯氮平与哌罗匹隆联合治疗对精神分裂症患者认知功能、生活质量的影响[J].黑龙江医药,2020,33(6):1342-1343.
     [4]Sinclair D, Purves-Tyson TD, Allen KM, et al. Impacts of stress and sex hormones on dopamine neurotransmission in the adolescent brain[J]. Psychopharmacology (Berl), 2014, 231(8):1581-1599.
     [5]王秀芹，钟远惠，江艳嫦. 行为矫正在女性精神分裂症患者中的应用[J]. 护理实践与研究，2017,14(6):140-141.
     [6]范肖东等译.ICD-10精神与行为障碍分类[M].北京：人民卫生出版社，1993：72-74.
     [7]汪向东.心理卫生评定量表手册[M].增订版.北京：中国心理卫生杂志社， 1999：267-276.
     [8]Morosini PL，Madiano L，Brambiua L, et al. Development，reliabiliity and acceptability of a new version of the DSM-IV social and occupational functioning assessment Scale(SOFAS) to assess routine social functioning[J].Acta Psychiatr Scand，2000，101(4)：323-329.
     [9]Afonso AC, Pacheco FD, Canever L, et al. Schizophrenia-like behavior is not altered by melatonin supplementation in rodents[J]. Anais da Academia Brasileira de Ciências, 2020, 92(4):113-119.
     [10]苏春丽.非典型抗精神病药物用于精神分裂症康复期治疗研究进展[J].中国处方药,2019,17(3):20-21.
     [11]张莉琳，谭成万，陈华，等.重复经颅磁刺激联合盐酸哌罗匹隆治疗精神分裂症患者疗效观察及对认知功能和生活质量的影响[J].国际精神病学杂志，2019，46(1)：109-112.
     [12]梁美娟，王海霞. 行为矫正训练对减少慢性精神分裂症患者不良行为的作用 [J]. 中国当代医药，2016，23(33)：50-52.
     [13]何燕,张敏桥,韩亚丽,等.齐拉西酮与帕利哌酮对女性精神分裂症患者PANS评分、催乳素及体质量的影响比较[J].中国基层医药,2017,24(20):3145-3148.
     [14]轩红艳, 王丽华. 抗精神病药导致的高泌乳素血症的干预措施[J]. 中华精神科杂志, 2019, 52(5):361-364.
     [15]于健瑾，宋佳起，赵青，等. 首发精神分裂症性激素与精神症状及认知功能关联性研究[J]. 中国神经精神疾病杂志, 2020, 46(8):16-21.

快速检索引用检索图表检索高级检索